Do thymic malignancies respond to target therapies? - Wikidata - wikimedia - TriplyDB

Do thymic malignancies respond to target therapies?

Do thymic malignancies respond to target therapies?

http://www.wikidata.org/entity/Q38371199

about

Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation

P2860

Q33655180-C3B14CFB-BEC2-4D7F-8B36-A9B9A5CFAC00

P2860

Do thymic malignancies respond to target therapies?

http://www.wikidata.org/entity/Q38371199

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Do thymic malignancies respond to target therapies?

@en

type

label

Do thymic malignancies respond to target therapies?

@en

prefLabel

Do thymic malignancies respond to target therapies?

@en

P1433

Q38371199-75416817-76D9-40E6-B410-BD99E8A4548D

P1476

Q38371199-B82942C9-E5BC-41E8-98DB-DAA184806A6B

P2093

Q38371199-40723F57-3587-47A8-A261-B419B7324741

Q38371199-5DF41A4D-939A-432D-8C90-9C0526744F81

Q38371199-73901759-490F-4863-AE88-2C219104D959

Q38371199-F9CC7D48-6FD8-4446-9970-88FB95AEEAF1

P2860

Q38371199-0CEE9711-15EA-497A-AA25-AA3D7534798C

Q38371199-115503E1-D642-4B12-873B-CE4BB693867D

Q38371199-1EE49F4D-B237-4939-8EE1-9910F88DAD4A

Q38371199-37D08142-59F7-4FE3-B1F7-3CB08F07EC5F

Q38371199-3DEACA00-3560-4B69-B393-ECCC1F2595F1

Q38371199-40A90300-B035-4732-8F51-118DAF9D4F1B

Q38371199-41ACBCD9-9D6E-466B-BEF5-3E57A3954F46

Q38371199-6465D125-9EA0-48F8-AB3A-FE754702AF62

Q38371199-755DACCC-A395-4233-BDC5-FC344C279698

Q38371199-7BDD8A4F-E198-4526-8DB7-11C40702EA56

P304

Q38371199-FA7C7DEF-A3C3-44D0-A02D-FFEEB0032D63

P31

Q38371199-9BC193A1-FDDC-429A-B33E-C13FBE651933

P356

Q38371199-C6E5834E-C7C4-4800-808F-A6C683BC06D7

P433

Q38371199-9FFA5F2F-42BE-4F91-BF10-DAAAE1528426

P478

Q38371199-FCF4FB76-F55C-4665-8FC0-A7F4E9B6C2E6

P577

Q38371199-D999479B-F529-47B3-B56D-948C3A6FF756

P5875

Q38371199-87FB507F-3FCB-4A5D-B219-CAF6E7EB8D15

P698

Q38371199-0A49B522-F37D-45B2-B39E-9CAA9CC67FAC

P356

P1433

Interactive cardio and thoracic surgery

P1476

Do thymic malignancies respond to target therapies?

@en

P2093

Bin Hu

http://www.w3.org/2001/XMLSchema#string

Hao Rong

http://www.w3.org/2001/XMLSchema#string

Qiang Li

http://www.w3.org/2001/XMLSchema#string

Yongtao Han

http://www.w3.org/2001/XMLSchema#string

P2860

Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.

Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses.

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.

Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.

Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.

Response of malignant thymoma to erlotinib.

Towards evidence-based medicine in cardiothoracic surgery: best BETS.

Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.

P304

855-859

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ICVTS/IVV040

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273385858

http://www.w3.org/2001/XMLSchema#string

P698

25754373

http://www.w3.org/2001/XMLSchema#string